The Journal of Urology
Volume 183, Issue 6 , Pages 2200-2205 , June 2010

Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer

  • Philip J. Saylor

      Affiliations

    • Corresponding Author InformationCorrespondence: Division of Hematology-Oncology, Massachusetts General Hospital Cancer Center, 55 Fruit St., Lawrence House/POB-2, Boston, Massachusetts 02114 (telephone: 617-643-1723; FAX: 617-724-3166)
    • ,
  • Donald S. Kaufman
    • ,
  • M. Dror Michaelson
    • ,
  • Richard J. Lee
    • ,
  • Matthew R. Smith

      Affiliations

    • Recipient of a National Institutes of Health K24 Midcareer Investigator Award (5K24CA121990-02) and grants from the Prostate Cancer Foundation.

Received 9 October 2009

References 

  1. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407
  2. Jiang HX, Majumdar SR, Dick DA, et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res. 2005;20:494
  3. Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab. 1999;84:3431
  4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (Report of a WHO Study Group). World Health Organ Tech Rep Ser. 1994;843:1
  5. Seeman E, Bianchi G, Khosla S, et al. Bone fragility in men–where are we?. Osteoporos Int. 2006;17:1577
  6. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385
  7. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16:1330
  8. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185
  9. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005;16:737
  10. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004;35:1029
  11. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893
  12. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375
  13. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16:155
  14. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. In: Washington, D. C: BoneSource; 2008;p. 1–37
  15. Watts NB, Lewiecki EM, Miller PD, et al. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008;11:473
  16. Dawson-Hughes B, Tosteson AN, Melton LJ, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449
  17. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361
  18. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181
  19. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219
  20. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948
  21. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154
  22. Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136
  23. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897
  24. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581
  25. Adler RA, Hastings FW, Petkov VI. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int. 2009;Epub ahead of print
  26. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599
  27. Douchi T, Kuwahata R, Matsuo T, et al. Relative contribution of lean and fat mass component to bone mineral density in males. J Bone Miner Metab. 2003;21:17
  28. NCCN. In: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer. vol. V:2009;2.2009
  29. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150
  30. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458

 Study was received institutional review board approval.

 See Editorial on page 2122.

PII: S0022-5347(10)00263-6

doi: 10.1016/j.juro.2010.02.022

The Journal of Urology
Volume 183, Issue 6 , Pages 2200-2205 , June 2010

Article Tools

* Image Usage & Resolution